Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Net (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Receivables - Net data on record, last reported at $891000.0 in Q4 2025.

  • For Q4 2025, Receivables - Net rose 39.66% year-over-year to $891000.0; the TTM value through Dec 2025 reached $891000.0, up 39.66%, while the annual FY2025 figure was $891000.0, 39.66% up from the prior year.
  • Receivables - Net reached $891000.0 in Q4 2025 per LCTX's latest filing, up from $127000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $891000.0 in Q4 2025 and bottomed at $77000.0 in Q1 2024.
  • Average Receivables - Net over 5 years is $346157.9, with a median of $323000.0 recorded in 2022.
  • Peak YoY movement for Receivables - Net: tumbled 99.55% in 2021, then skyrocketed 450.63% in 2022.
  • A 5-year view of Receivables - Net shows it stood at $79000.0 in 2021, then skyrocketed by 275.95% to $297000.0 in 2022, then skyrocketed by 135.69% to $700000.0 in 2023, then dropped by 8.86% to $638000.0 in 2024, then skyrocketed by 39.66% to $891000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $891000.0 in Q4 2025, $127000.0 in Q3 2025, and $256000.0 in Q2 2025.